9月19日，港股通创新药板块早盘冲高回落后，维持红盘震荡。MIRXES-B一枝独秀，午后一度暴拉 25%，诺诚健华、同源康医药-B大涨超5%居前，权重股信达生物涨超2%。 100%创新药研发标的——港股通创新药ETF（520880）盘初一度上探2.57%，截至发稿仍涨超1%，成 交突破3亿元。 消息面，私募排排网数据显示，截至9月12日，全市场股票私募机构平均仓位超过78%，较9月5日上升 近3个百分点，达到今年最高水平。多家百亿级私募近期透露，目前仓位维持中高水平，并逢低加码创 新药等板块的优质标的。业内人士认为，从长期看，中国优势产业的全球竞争力没有变，中国经济修复 趋势未变，A股和港股的结构性行情有望持续演绎。 对此，港股通创新药ETF（520880）近期资金面有所印证。数据显示，截至9月19日，520880已连续14 日吸金，金额合计近6.8亿元。兴证全球策略首席张忆东日前提示，9月份或是创新药布局良机。 港股通创新药ETF（520880）基金经理丰晨成认为，现在应保持对创新药板块的密切关注，而非"退 场"。短期的市场调整，反而可能给真正质优的创新药企业提供了一次难得的买点。具体来看，当前创 新药仍有 ...

Group 1 - The Hang Seng Index declined by 0.32% and the Hang Seng Tech Index fell by 0.68% [1] - Kuaishou experienced a drop of over 6% [1] - Pharmaceutical stocks showed strength, with Nuo Cheng Jian Hua rising by over 3% [1]

Group 1 - The pharmaceutical stocks have generally risen, with notable increases in companies such as WuXi AppTec (6.82% increase), Innovent Biologics (5.72% increase), and WuXi Biologics (3.86% increase) [1] - The National Healthcare Security Administration has released the 11th batch of centralized procurement documents for drugs, emphasizing principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition" [1] - The optimization of price control benchmarks in the procurement process indicates a shift away from simply selecting the lowest bid, reflecting a proactive approach by the healthcare authority to improve the domestic market [1] Group 2 - Guojin Securities expresses strong confidence in a reversal trend for the pharmaceutical sector in 2025, highlighting innovative drugs and the recovery of left-behind sectors as significant investment opportunities [2] - The upward trend in the innovative drug industry remains intact, with multinational corporations facing patent cliffs and likely to continue using business development strategies to fill revenue gaps [2] - Dongwu Securities notes that the easing interest rate environment is expected to enhance the prosperity of the innovative industry chain, benefiting upstream biotech and CXO sectors [2]

每经AI快讯，9月22日，港股医药股多数上扬。截至发稿，药明合联(02268.HK)涨6.82%，报75.2港元； 诺诚健华(09969.HK)涨5.72%，报17.38港元；药明生物(02269.HK)涨3.86%，报39.24港元；歌礼制药- B(01672.HK)涨3.09%，报11.01港元；恒瑞医药(01276.HK)涨2.74%，报90港元。 ...

Group 1 - The pharmaceutical stocks are mostly rising, with notable increases in companies such as WuXi AppTec (02268) up 6.82% to HKD 75.2, Innovent Biologics (09969) up 5.72% to HKD 17.38, and WuXi Biologics (02269) up 3.86% to HKD 39.24 [1] - The National Healthcare Security Administration has released the 11th batch of centralized procurement documents for drugs, emphasizing principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition" [1] - The procurement plan optimizes the selection of price control "anchors," moving away from simply choosing the lowest bid, which reflects a proactive approach by the healthcare authority to promote a healthier domestic market [1] Group 2 - Guojin Securities expresses strong confidence in a reversal trend for the pharmaceutical sector in 2025, identifying innovative drugs and the left-side sector's recovery as the biggest investment opportunities [2] - The upward trend in the innovative drug industry remains unchanged, with multinational corporations facing patent cliffs and likely to continue using business development (BD) strategies to fill revenue gaps [2] - Dongwu Securities notes that in a context of interest rate cuts, the innovative industry chain's prosperity is expected to improve, benefiting upstream biotech and CXO sectors [2]

Group 1 - The Hang Seng Index opened down 0.32%, the Hang Seng Tech Index down 0.68%, and the National Enterprises Index down 0.42% [1] - Consumer stocks showed weakness, with Anta Sports down over 4% and Kuaishou opening down 6.3% due to regulatory scrutiny over harmful information [1] - Pharmaceutical stocks generally rebounded, with Innovent Biologics rising over 3%, and Hongteng Precision opening nearly 7% close to historical highs [1] Group 2 - In the first eight months, the amount of goods eligible for tax refunds at Shanghai's exit exceeded 2 billion yuan, surpassing the total for the previous year [1] - The Shanghai Customs reported a significant increase in tax refund applications, with 96,600 applications and a total amount of 2.07 billion yuan, representing a year-on-year growth of 168% and 83% respectively [1] - The Hongqiao Airport Customs also performed well, with 3,329 tax refund applications and a total amount of 125 million yuan, showing year-on-year increases of 140% and 31% respectively [1] Group 3 - Relevant popular ETFs include the Tourism ETF (562510), which may benefit from the upcoming Mid-Autumn Festival and National Day holidays, and the Food and Beverage ETF (515170) that focuses on core assets in the "food and drink sector" [2] - The Consumption 30 ETF (510630) covers various sub-sectors including liquor, food, beauty care, and biotechnology [2] - The Hong Kong Consumption ETF (513230) aggregates leading internet consumption stocks in Hong Kong [2]

Group 1 - The Hong Kong stock market opened slightly lower on September 22, with the Hang Seng Index at 26,459.52 points, down 85.58 points, a decrease of 0.32% [1] - BYD responded to reports that Berkshire Hathaway had completely divested its shares in the company, confirming that Berkshire began reducing its stake in August 2022 and was below 5% by June 2024 [3] - Shandong High-Speed Holdings confirmed no unusual reasons for stock price and trading volume fluctuations, stating that business operations and financial conditions remain stable [5] Group 2 - The technology sector saw declines, with NetEase down over 1% and Alibaba down nearly 1%, while the innovative drug concept stocks opened higher, with Innovent Biologics up over 3% [7] - AI remains a key theme in the Hong Kong market, with internet stocks expected to benefit significantly; the non-ferrous metals sector is also poised to gain from interest rate cuts and inflation expectations [8] - The MACD golden cross signal has formed, indicating positive momentum for certain stocks [9]

Group 1 - The non-ferrous cobalt concept is showing strong performance across the board, while the consumption electronics sector is active, and the robotics and oil and gas sectors are experiencing declines [1][2] - The A-share market opened with all three major indices rising: Shanghai Composite Index up 0.05%, Shenzhen Component Index up 0.37%, and ChiNext Index up 0.10% [1][2] Group 2 - The Hong Kong stock market opened with the Hang Seng Index down 0.32% and the Hang Seng Tech Index down 0.68%, with notable declines in Kuaishou, which fell over 6% due to an investigation into its e-commerce operations [3] - Pharmaceutical stocks generally rebounded, with Nocera Healthcare rising over 3%, while Hongteng Precision opened nearly 7% higher, approaching historical highs [3] Group 3 - Anta Sports saw a decline of over 4% following an apology related to a sponsorship incident involving fireworks in the Himalayas [4][5]

Group 1 - The non-ferrous cobalt concept is showing strong performance across the board, while the consumption electronics sector is active, and the robotics and oil & gas sectors are experiencing declines [1][3] - The A-share Apple supply chain is active at the opening, with Luxshare Precision hitting the daily limit, and several other stocks such as GoerTek, Darui Electronics, Lens Technology, and others opening high [1] - The Hong Kong stock market opened with the Hang Seng Index down 0.32% and the Hang Seng Tech Index down 0.68%, with notable declines in Kuaishou and Anta Sports [4] Group 2 - The A-share market opened with all three major indices rising slightly, with the Shanghai Composite Index up 0.05%, the Shenzhen Component Index up 0.37%, and the ChiNext Index up 0.10% [2][3] - The People's Bank of China conducted a 240.5 billion yuan 7-day reverse repurchase operation at an interest rate of 1.40%, along with a 300 billion yuan 14-day reverse repurchase operation [5]

Investment Rating - The report maintains an investment rating of "Outperform the Market" [5] Core Insights - The new drug sector has shown significant movements, with notable increases in stock prices for companies such as Kintor Pharmaceutical, which recently went public in Hong Kong, focusing on unmet clinical needs in oncology and immunology [2][3][21] - The KRAS G12D inhibitor GFH375 from Kintor Pharmaceutical has demonstrated promising clinical data in treating pancreatic cancer and non-small cell lung cancer (NSCLC), with an overall response rate (ORR) of 52% in pancreatic cancer and 68.8% in NSCLC [21][24] Summary by Sections Weekly New Drug Market Review - From September 15 to September 21, 2025, the top five gainers in the new drug sector included Kintor Pharmaceutical (+19.64%), Boan Biotechnology (+8.89%), and others, while the top five losers included Sanofi Pharmaceuticals (-17.16%) and others [1][13] Recommended Stocks to Watch - The report suggests focusing on several potential catalysts in the sector, including academic conferences and insurance negotiations. Key companies to watch include: 1. Differentiated GLP-1 assets: Zai Lab, EQRx, and others 2. Upgraded PD-1 products: CanSino Biologics and others 3. Companies likely to benefit from insurance negotiations: Hengrui Medicine, Kanghong Pharmaceutical, and others [2][17] New Drug Approval and Acceptance - This week, eight new drug applications were approved, and twelve new drug applications were accepted in China [3][25] Clinical Application Approvals - A total of 48 new drug clinical applications were approved, with 32 applications accepted this week [7][29]